CN1016785B - 9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法 - Google Patents

9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法

Info

Publication number
CN1016785B
CN1016785B CN88104331A CN88104331A CN1016785B CN 1016785 B CN1016785 B CN 1016785B CN 88104331 A CN88104331 A CN 88104331A CN 88104331 A CN88104331 A CN 88104331A CN 1016785 B CN1016785 B CN 1016785B
Authority
CN
China
Prior art keywords
dihydrate
homoerythromycin
methyl
water content
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CN88104331A
Other languages
English (en)
Chinese (zh)
Other versions
CN1030422A (zh
Inventor
道格拉斯·约翰·梅尔德伦·艾伦
凯文·迈克尔·内普弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22202456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1016785(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CN1030422A publication Critical patent/CN1030422A/zh
Publication of CN1016785B publication Critical patent/CN1016785B/zh
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN88104331A 1987-07-09 1988-07-08 9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法 Expired CN1016785B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1987/001612 WO1989000576A1 (en) 1987-07-09 1987-07-09 Azithromycin dihydrate
USPCT/US87/01612 1987-07-09

Publications (2)

Publication Number Publication Date
CN1030422A CN1030422A (zh) 1989-01-18
CN1016785B true CN1016785B (zh) 1992-05-27

Family

ID=22202456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN88104331A Expired CN1016785B (zh) 1987-07-09 1988-07-08 9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法

Country Status (45)

Country Link
US (1) US6268489B1 (enExample)
EP (1) EP0298650B1 (enExample)
JP (1) JPH0631300B2 (enExample)
KR (1) KR900006218B1 (enExample)
CN (1) CN1016785B (enExample)
AP (1) AP44A (enExample)
AR (1) AR243532A1 (enExample)
AT (1) ATE72446T1 (enExample)
AU (1) AU604553B2 (enExample)
BA (1) BA98213B1 (enExample)
BG (1) BG47348A3 (enExample)
CA (1) CA1314876C (enExample)
CS (1) CS272241B2 (enExample)
CY (1) CY1776A (enExample)
DD (1) DD271705A5 (enExample)
DE (1) DE3868296D1 (enExample)
DK (1) DK172573B1 (enExample)
EG (1) EG18527A (enExample)
ES (1) ES2038756T3 (enExample)
FI (1) FI91263C (enExample)
GR (1) GR3003737T3 (enExample)
HK (1) HK127594A (enExample)
HU (1) HU211862A9 (enExample)
IE (1) IE60354B1 (enExample)
IL (1) IL86979A (enExample)
IN (1) IN168879B (enExample)
IS (1) IS1540B (enExample)
LV (1) LV10624B (enExample)
MA (1) MA21323A1 (enExample)
MX (1) MX12213A (enExample)
MY (1) MY103744A (enExample)
NO (1) NO171556C (enExample)
NZ (1) NZ225338A (enExample)
OA (1) OA08743A (enExample)
PH (1) PH30953A (enExample)
PL (1) PL157145B1 (enExample)
PT (1) PT87933B (enExample)
RO (1) RO107257B1 (enExample)
RU (1) RU2066324C1 (enExample)
SG (1) SG27794G (enExample)
SI (1) SI8811325A8 (enExample)
UA (1) UA27040C2 (enExample)
WO (1) WO1989000576A1 (enExample)
YU (1) YU45075B (enExample)
ZA (1) ZA884925B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308361C (zh) * 2004-08-09 2007-04-04 大连振邦氟涂料股份有限公司 乙烯－三氟氯乙烯共聚物的制备方法
CN100366686C (zh) * 2006-01-12 2008-02-06 济南瑞氟化工科技有限公司 一种氟硅超双疏不粘涂料

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
US5912331A (en) * 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5189159A (en) * 1992-04-02 1993-02-23 Merck & Co., Inc. 8a-AZA-8a-homoerythromycin cyclic iminoethers
EP0539223A1 (en) * 1991-10-25 1993-04-28 Ono Pharmaceutical Co., Ltd. Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
US5210235A (en) * 1992-08-26 1993-05-11 Merck & Co., Inc. Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics
US5332807A (en) * 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
CN1034734C (zh) * 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
SI9520049A (en) * 1994-05-06 1997-12-31 Pfizer Controlled-release dosage forms of azithromycin
ES2122905B1 (es) * 1996-07-11 1999-11-16 Astur Pharma Sa Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
EP1036083B9 (en) * 1997-10-16 2005-01-12 Pliva - Istrazivacki Institut d.o.o. Novel 9a-azalides
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
PT102130A (pt) * 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
IL143376A0 (en) * 1998-11-30 2002-04-21 Teva Pharma Ethanolate of azithromycin, process for the manufacture, and pharmaceutical compositions thereof
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE60038610T2 (de) * 1999-05-18 2009-06-25 Pfizer Products Inc., Groton Neue kristalline formen eines makrolidantibiotikums
DE60029589T2 (de) * 1999-06-29 2007-07-19 Sandoz Ag Verfahren zur herstellung von azithromycin
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CA2396426A1 (en) 2000-01-04 2001-07-12 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (es) * 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
AU2000270425A1 (en) 2000-07-25 2002-02-13 Instituto De Investigacion En Quimica Aplicada S.C Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydr oxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin
ES2172417B1 (es) * 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
EP1313749B1 (en) 2000-08-23 2005-10-12 Wockhardt Limited Process for preparation of anhydrous azithromycin
EP1339730A2 (en) * 2000-11-27 2003-09-03 Biochemie S.A. Macrolide solvates
UA76967C2 (uk) * 2000-11-27 2006-10-16 Сандоз Аг Азитроміцин у формі моногідрату, фармацевтична композиція та спосіб його одержання
IN190080B (enExample) * 2001-01-29 2003-06-07 Alembic Ltd
KR100491183B1 (ko) * 2001-03-21 2005-05-25 한미약품 주식회사 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EA007618B1 (ru) * 2001-05-22 2006-12-29 Пфайзер Продактс Инк. Кристаллический полуторогидрат азитромицина, содержащая его фармацевтическая композиция и способ лечения на его основе
SI1390377T1 (sl) 2001-05-22 2006-06-30 Pfizer Prod Inc Nova kristalna oblika azitromicina
GEP20063812B (en) * 2001-08-21 2006-05-10 Pfizer Prod Inc Single dose azithromycin for treating respirator infections
RU2283651C2 (ru) * 2001-12-21 2006-09-20 Пфайзер Продактс Инк. Способы мокрой грануляции азитромицина
NZ532707A (en) * 2001-12-21 2006-07-28 Pfizer Prod Inc Directly compressible formulations of azithromycin
AU2003201146B2 (en) * 2002-02-01 2008-04-17 Pfizer Products Inc. Dry granulated formulations of azithromycin
US7376064B2 (en) 2002-02-25 2008-05-20 Samsung Electronics Co., Ltd. Method and apparatus for recording data on optical recording medium
ITMI20021209A1 (it) * 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza
US6855813B2 (en) * 2002-07-19 2005-02-15 Alembic Limited Process for the preparation of azithromycin monohydrate
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
GB2395482A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Process for preparing non-hygroscopic azithromycin dihydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
EP1689368B1 (en) * 2003-12-04 2016-09-28 Bend Research, Inc Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions
WO2005053640A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
KR100844628B1 (ko) * 2003-12-04 2008-07-07 화이자 프로덕츠 인크. 제약상 다입자의 제조 방법
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
RU2260012C1 (ru) * 2004-01-29 2005-09-10 Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" Способ кристаллизации азитромицина дигидрата
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US7235646B2 (en) 2004-06-28 2007-06-26 Alembic Limited Process for the preparation of azithromycin monohydrate isopropanol clathrate
US7683162B2 (en) * 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
MX2007005222A (es) * 2004-12-01 2007-06-26 Teva Gyogyszergyar Zartkoruen Pimecrolimus amorfo no higroscopico y en polvo.
CA2591923A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP2009539866A (ja) * 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
US7704959B2 (en) 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
US20090062220A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched azithromycin
CN101177441B (zh) * 2007-12-05 2012-05-23 浙江耐司康药业有限公司 一种稳定的阿奇霉素一水合物结晶的制备方法
CN101624412B (zh) * 2008-07-10 2012-07-04 刘力 大环内酯类衍生物及其制备和用途
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
BRPI0920026B1 (pt) 2008-10-07 2023-11-07 Horizon Orphan Llc Composição farmacêutica e respectivos usos
CN101418026B (zh) * 2008-10-09 2011-05-18 南京工业大学 一种晶型和粒度可控的阿奇霉素结晶工艺
CN101787063B (zh) * 2009-01-23 2012-12-19 刘力 抗感染药物及其制备和用途
JP2012520268A (ja) 2009-03-13 2012-09-06 ダ・ボルテラ グラム陰性細菌の除去のための組成物及び方法
MX353288B (es) 2009-09-04 2018-01-08 Raptor Pharmaceuticals Inc Uso de levofloxacina aerosolizada para el tratamiento de fibrosis quistica.
CN102911219A (zh) * 2011-08-03 2013-02-06 山东方明药业集团股份有限公司 一种阿齐霉素在水相直接结晶的方法
CN103159811A (zh) * 2011-12-10 2013-06-19 山东方明药业集团股份有限公司 一种阿齐霉素中间体9a-脱氧-9a-氮杂-9a-高红霉素A的制备方法
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
CN102417531B (zh) * 2011-12-20 2014-06-11 浙江国邦药业有限公司 一种阿奇霉素一水合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020270A (en) * 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
US4219641A (en) * 1979-06-14 1980-08-26 The Upjohn Company Process for preparing erythromycin succinate
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4526889A (en) * 1982-11-15 1985-07-02 Pfizer Inc. Epimeric azahomoerythromycin A derivative, intermediates and method of use
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
YU43402B (en) * 1985-03-04 1989-06-30 Pliva Pharm & Chem Works Process for preparation of 11-aza-10-deoxo-10-dihydroeritromycin "a" by using electro-chemical reduction
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308361C (zh) * 2004-08-09 2007-04-04 大连振邦氟涂料股份有限公司 乙烯－三氟氯乙烯共聚物的制备方法
CN100366686C (zh) * 2006-01-12 2008-02-06 济南瑞氟化工科技有限公司 一种氟硅超双疏不粘涂料

Also Published As

Publication number Publication date
SG27794G (en) 1994-10-14
IL86979A0 (en) 1988-12-30
NO171556B (no) 1992-12-21
ZA884925B (en) 1990-02-28
IL86979A (en) 1992-11-15
FI900087A0 (fi) 1990-01-08
NO900077D0 (no) 1990-01-08
MA21323A1 (fr) 1989-04-01
AR243532A1 (es) 1993-08-31
NO171556C (no) 1993-03-31
UA27040C2 (uk) 2000-02-28
NZ225338A (en) 1990-02-26
RO107257B1 (ro) 1993-10-30
BG47348A3 (bg) 1990-06-15
FI91263B (fi) 1994-02-28
MY103744A (en) 1993-09-30
DK172573B1 (da) 1999-01-25
OA08743A (fr) 1989-03-31
IN168879B (enExample) 1991-06-29
EP0298650A3 (en) 1989-11-08
CA1314876C (en) 1993-03-23
EP0298650B1 (en) 1992-02-05
FI900087L (fi) 1990-01-08
PL273590A1 (en) 1989-03-20
JPH0631300B2 (ja) 1994-04-27
IS1540B (is) 1994-01-28
MX12213A (es) 1993-05-01
DE3868296D1 (de) 1992-03-19
WO1989000576A1 (en) 1989-01-26
LV10624B (en) 1995-10-20
AU1883988A (en) 1989-01-12
YU45075B (en) 1991-08-31
JPS6438096A (en) 1989-02-08
ES2038756T3 (es) 1993-08-01
LV10624A (lv) 1995-04-20
CN1030422A (zh) 1989-01-18
NO900077L (no) 1990-01-08
KR890002137A (ko) 1989-04-08
PT87933B (pt) 1994-09-30
CS489688A2 (en) 1990-03-14
CS272241B2 (en) 1991-01-15
KR900006218B1 (ko) 1990-08-25
IS3370A7 (is) 1989-01-10
PH30953A (en) 1997-12-23
US6268489B1 (en) 2001-07-31
HK127594A (en) 1994-11-25
ATE72446T1 (de) 1992-02-15
DK380688D0 (da) 1988-07-08
SI8811325A8 (en) 1996-12-31
EG18527A (en) 1993-10-30
AP44A (en) 1989-07-27
DK380688A (da) 1989-01-10
EP0298650A2 (en) 1989-01-11
IE882108L (en) 1989-01-09
AP8800093A0 (en) 1988-05-01
AU604553B2 (en) 1990-12-20
IE60354B1 (en) 1994-06-29
PT87933A (pt) 1989-06-30
CY1776A (en) 1995-10-20
HU211862A9 (en) 1995-12-28
PL157145B1 (en) 1992-04-30
FI91263C (fi) 1994-06-10
RU2066324C1 (ru) 1996-09-10
BA98213B1 (bs) 1999-08-02
YU132588A (en) 1990-02-28
GR3003737T3 (enExample) 1993-03-16
DD271705A5 (de) 1989-09-13

Similar Documents

Publication Publication Date Title
CN1016785B (zh) 9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法
CA2584365A1 (en) Ascomycin crystalline forms and preparation thereof
CN1028428C (zh) 23-(c1-c6烷基肟)-ll-f28249化合物的制备方法
EP0579681A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
AU2004320911A8 (en) 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine oxalate (donepezil oxalate) and its polymorphs
US7186842B2 (en) Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof
US4322402A (en) Germanium-containing organic polymer and its use in the treatment of allergic disease
KR100912664B1 (ko) 레르카니디핀 염산의 용매화물 및 레르카니디핀 염산의신규 결정형
CN102382169B (zh) 阿加曲班单一立体异构体的分离方法及多晶型物
BG65587B1 (bg) Дифосфатна сол на производно на 4"- заместен-9-деоксо- 9а-аза-9а-хомоеритромицин и фармацевтичния йсъстав
US20070123565A1 (en) Donepezil Hydrochloride Form VI
CA1101439A (en) O-HEMI-SUCCINATES OF .beta.-ADRENERGIC BLOCKING COMPOUNDS
KR20020050282A (ko) 베타-디-5-티옥실로스 유도체, 제조방법 및 약학적 용도
CN112694488B (zh) 一种l型头孢孟多酯钠的合成方法
EP0619816A1 (en) A process for the resolution of (+-)-alpha-[2-[acetyl(1-methylethyl)amino]ethyl]-alpha-(2-chlorophenyl)-1-piperidinebutanamide
CN86102199A (zh) 19-脱氧糖苷配基猎神霉素结晶无水钠盐的制备方法
EP0548834B1 (en) Stable hexahydrate of etoposide 4'-phosphate disodium salt
JPH0285235A (ja) 光学活性アミノアルコール類の製法
CN102329371A (zh) 阿加曲班单一立体异构体的分离方法及多晶型物
WO1999033797A1 (en) NEW CRYSTALLINE POLYMORPHIC FORM OF 1-METHYL-5-p-TOLUOYLPYRROLE-2-ACETAMIDOACETIC ACID GUAIACYL ESTER (MED 15)
CN1854142A (zh) 呋脲苄青霉素钠的结晶方法
HK1064381A (en) 3-(3-amidinophenyl)-5-[({[1-(1-(-iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same
EP1771416A1 (en) A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof
CN1269354A (zh) 再结晶1,3－二(氨基苯氧基苯)的方法
JPH023627A (ja) 光学活性１−メチル−３−フェニルプロピルアミンの製造法

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C13 Decision
GR02 Examined patent application
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term